10x Genomics Profit Margin

The latest profit margin for TXG is -12.18% as of June 2026. That compares with -13.13% in the prior-year period — up 7.2% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside 10x Genomics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TXG's profit margin moved from -13.13% to -12.18% — a 7.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 10x Genomics's valuation or profitability profile.

Against Healthcare companies, TXG currently prints -12.18% for profit margin, while the sector average sits near 21.34%. That is roughly 157.1% below the sector mean. Large gaps often invite a closer look at 10x Genomics's growth, margins, and balance sheet.

Profit Margin shows how effectively 10x Genomics converts resources into returns. At -12.18%, TXG may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -13.13% in the prior-year period — up 7.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TXG's profit margin (-12.18%), review year-over-year change from -13.13%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.